Oncotarget

Research Papers:

GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma

Yung-Kuan Tsou, Kung-Hao Liang _, Wey-Ran Lin, Hsien-Kun Chang, Chen-Kan Tseng and Chau-Ting Yeh

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:29151-29160. https://doi.org/10.18632/oncotarget.16253

Metrics: PDF 1021 views  |   HTML 1655 views  |   ?  


Abstract

Yung-Kuan Tsou1, Kung-Hao Liang1,2,3, Wey-Ran Lin1,2,4, Hsien-Kun Chang5, Chen-Kan Tseng6, Chau-Ting Yeh1,2,3,4

1Department of Hepato-Gastroenterology, Chang Gung Memorial Hospital, Taoyuan, Taiwan

2Liver Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan

3Molecular Medicine Research Center, Chang Gung University, Taoyuan, Taiwan

4Chang Gung University, College of Medicine, Taoyuan, Taiwan

5Department of Oncology, Chang Gung Memorial Hospital, Taoyuan, Taiwan

6Department of Radiation Oncology, Chang Gung Memorial Hospital, Taoyuan, Taiwan

Correspondence to:

Kung-Hao Liang, email: kunghao@gmail.com

Chau-Ting Yeh, email: chautingy@gmail.com

Keywords: germline polymorphism, biomarker, cisplatin, gastrointestinal cancer, pharmacogenomics

Received: November 22, 2016    Accepted: February 20, 2017    Published: March 16, 2017

ABSTRACT

Esophageal squamous cell carcinoma is an aggressive cancer. We investigated genetic response predictors for patients with advanced esophageal squamous cell carcinoma receiving concurrent chemoradiotherapy. A cohort of 108 patients was recruited. Survival analysis showed that lower esophageal location of tumor, more advanced metastasis stage, and longer length of tumor were associated with poorer overall survival (adjusted P = 0.001, < 0.001, and 0.045, respectively), while the presence of complete/partial response to concurrent chemoradiotherapy was independently associated with better overall survival (adjusted P < 0.001). The GALNT14-rs9679162 “GG” genotype was associated with a lower rate of response (P = 0.014). Multivariate Cox-proportional hazards models also showed that the “GG” genotype was associated with a longer time to complete/partial response (adjusted P = 0.022), independent of leukocyte counts and gender. In conclusion, the presence of a complete/partial response to chemoradiotherapy was critical for advanced esophageal squamous cell carcinoma patients to achieve better overall survival. The GALNT14-rs9679162 “GG” genotype was associated with a longer time to complete/partial response of concurrent chemoradiotherapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16253